Advances in the biology and therapeutic management of multiple myeloma

Kaufmann, H.; Urbauer, E.; Ackermann, J.; Huber, H.; Drach, J.
August 2001
Annals of Hematology;Aug2001, Vol. 80 Issue 8, p445
Academic Journal
During the past decade, new developments have increased our understanding of the biological features of multiple myeloma (MM), and novel therapeutic approaches have improved the outcome and quality of life. The importance of both the malignant clone and the bone marrow environment for disease evolution and propagation has been recognized, and therapeutic approaches that target both components of the disease process appear to be most promising. Along this line, thalidomide has been observed to exert activity in chemotherapy-refractory MM and thus expands the therapeutic armamentarium against MM. Use of high-dose melphalan with autologous stem cell transplantation has resulted in an improved rate of complete remissions as well as prolonged event-free and overall survival. Novel treatment strategies exploiting anti-myeloma immunity (nonmyeloablative allogeneic transplantation, vaccination) are being investigated and carry the potential to further improve the outcome of patients with MM.


Related Articles

  • Extramedullary progression of multiple myeloma despite a good response in the bone marrow in a patient following autologous stem cell transplantation. Kose, Mustafa; Sonnez, Mehmet; Cobanoglu, Umit; Yilmaz, Mustafa; Karti, S. Sami; Ovali, Ercument; Ozoran, Yavuz // Turkish Journal of Cancer;Apr2003, Vol. 33 Issue 2, p102 

    Extramedullary plasmacytomas may be seen in the course of multiple myeloma. However, extramedullary progression despite good response in the bone marrow to therapy is extremely rare. Recently, two cases of multiple with extramedullary progression despite continued response to thalidomide in the...

  • Cure of multiple myeloma – more hype, less reality. Hari, P.; Pasquini, M. C.; Vesole, D. H. // Bone Marrow Transplantation;Jan2006, Vol. 37 Issue 1, p1 

    Randomized studies have firmly established the role of autologous transplant as initial therapy in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous SCT in North America. The conceptual basis for high-dose therapy is the goal of complete remission (CR)...

  • Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma. Shin Kim; Hyo-Jung Kim; Jung Sun Park; Jungsin Lee; Hyun-Sook Chi; Chan Jeong Park; Jooryung Huh; Cheolwon Suh // Annals of Hematology;Nov2005, Vol. 84 Issue 11, p742 

    In patients with hematologic malignancies, granulocyte colony-stimulating factor (G-CSF) following chemotherapy is widely used to mobilize peripheral blood progenitor cells (PBPCs), but there have been no trials comparing schedules of G-CSF following chemotherapy. We conducted a prospective...

  • Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Boccadoro, Mario; Morgan, Gareth; Cavenagh, Jamie // Cancer Cell International;2005, Vol. 5, p18 

    Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for single-agent use in the treatment of patients with multiple myeloma who have received at least 2 prior therapies and are progressing on their most recent therapy. Clinical investigations have been...

  • An unusual presentation of a secondary extramedullary plasmacytoma in a patient with multiple myeloma. Dzierzanowski, Martin; Porter, Geoffrey A. // Canadian Journal of Surgery;Feb2005, Vol. 48 Issue 1, p75 

    The article presents a medical case of an unusual presentation of a secondary extramedullary plasmacytoma in a patient with multiple myeloma (MM). MM belongs to the family of monoclonal, immunoproliferative plasma-cell neoplasms (plasmacytomas) arising from the B-cell line. Malignant...

  • Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis. Rinn, J. P.; Schwella, N.; Wollmer, E.; Jaques, G.; Heinzel-Gutenbrunner, M.; Strassmann, G.; Gross, M. w.; Movassaghi, K.; Neubauer, A.; Ritter, M. // Annals of Hematology;Jan2006, Vol. 85 Issue 1, p38 

    In patients with multiple myeloma, irradiation of bone marrow prior to mobilization of autologous peripheral blood progenitor cells (PBPCs) may lead to a reduced yield of CD34+ cells. Quantitative effects have not been sufficiently assessed. We retrospectively performed a multivariate analysis...

  • Bortezomib, a Newly Approved Proteasome Inhibitor for the Treatment of Multiple Myeloma: Nursing Implications. Colson, Kathleen; Doss, Deborah S.; Swift, Regina; Tariman, Joseph; Thomas, Teri E. // Clinical Journal of Oncology Nursing;Oct2004, Vol. 8 Issue 5, p473 

    Multiple myeloma (MM), a malignancy of the plasma cells, accounts for an estimated 14% of all newly diagnosed hematologic malignancies. Advances in chemotherapy and stem cell transplantation have improved survival rates, but MM remains incurable. Bortezomib (Velcadeâ„¢, Millennium...

  • CITATIONS AND CLINICIANS' NOTES: MYELOMA.  // Current Medical Literature: Leukemia & Lymphoma;2004, Vol. 12 Issue 4, p90 

    Presents citations and clinicians' notes on myeloma. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization; Efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia; Relation between CXC chemokine receptor 4 expression, Flt3...

  • Continuous therapy with lenalidomide in multiple myeloma.  // British Journal of Hospital Medicine (17508460);Jan2010, Vol. 71 Issue 1, p10 

    The article offers information on the data that evaluates the continuous therapy with Revlimid across all stage of multiple myeloma in the U.S. The data presented during the American Society of Hematology congress demonstrated that lenalidomide has a significant clinical potential in active...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics